Photo: Michael Ciaglo / Getty Images
For: The Opinion
Thursday, October 3
Health Authorities Evaluate J&J Vaccine Restrictions in Fatal Blood Clots
The Centers for Disease Control and Prevention (CDC) were scheduled to meet with counselors on Thursday to discuss possible restrictions on the COVID vaccine – 19 by Johnson & Johnson , due to ongoing concerns about blood clots, particularly among women.
Federal officials temporarily halted use J&J single-dose vaccine in April, to study six women who had experienced blood clots after being vaccinated.
The government ruled that The benefits far outweighed the risks associated with the injection, and use of the vaccine was resumed a few days later with a new warning label.
Although complications remain rare, nails Nine American women have died after experiencing vaccine-associated blood clots , and the rate of clots in people who received the vaccine has risen since April, The Washington Post reported Wednesday.
Approximately each 100, from between 30 and 49 years ago had experienced clot problems after receiving a J&J injection, the FDA said in a fact sheet published Tuesday.
The Advisory Committee on Immunization Practices was expected to vote on restricting the use of the J&J initial and booster injection or issue a preferential recommendation for other vaccines, according to the document.
Any recommendation should be reviewed by the CDC, which supposedly asked the departments state health agencies to assess how dependent they were on the vaccine.
“We are committed to understanding and communicating all known risks, including events rare of (the blood clot condition), and we strongly support raising awareness of the signs and symptoms of this rare event, ”reported Jake Sargent, spokesperson for Johnson & Johnson.
They have only been distributed around 17 million doses of J&J in the United States, compared to about 470 million doses of Pfizer vaccines and Modern, according to the CDC.